ADC Therapeutics S.A. (ADCT) News
Filter ADCT News Items
ADCT News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ADCT News Highlights
- ADCT's 30 day story count now stands at 2.
- Over the past 3 days, the trend for ADCT's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- ADC, FL and DEC are the most mentioned tickers in articles about ADCT.
Latest ADCT News From Around the Web
Below are the latest news stories about ADC THERAPEUTICS SA that investors may wish to consider to help them evaluate ADCT as an investment opportunity.
ADC Therapeutics SA (NYSE:ADCT) institutional owners may be pleased with recent gains after 46% loss over the past yearKey Insights Institutions' substantial holdings in ADC Therapeutics implies that they have significant influence over... |
ADC Therapeutics Announces Initial Results from Investigator-Initiated Phase 2 Clinical Trial Evaluating ZYNLONTA® in Combination with Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma (FL)Combination demonstrated clinically meaningful benefit in r/r FL patients with 96% overall response rate and 85% complete response rate LAUSANNE, Switzerland, Dec. 12, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced initial results from an investigator-initiated Phase 2 clinical trial evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with rituximab demonstrated a high response rate in patients with relapsed or refractory (r/r) follicular lymphoma (FL). T |
Sobi to present new data at ASH 2023 Annual MeetingSobi® will present new data at the 65th Annual Meeting of the American Society of Hematology (ASH) in San Diego from the 9th to the 12th of December 2023. During the meeting several analyses will be presented in patients with haemophilia A, paroxysmal nocturnal hemoglobinuria (PNH), immune thrombocytopenia (ITP), relapsed or refractory diffuse large b-cell lymphoma, myelofibrosis, and haemophagocytic lymphohistiocytosis. |
Myricx Bio Appoints Dr Chris Martin, Biotech Entrepreneur and ADC Pioneer, as Chairman of its Board of DirectorsDr Chris Martin Dr Chris Martin, Chairman of Myricx LONDON, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Myricx Bio (‘Myricx’), a UK biotech company focused on the discovery and development of a completely novel class of antibody-drug conjugate (ADC) payloads based on N-Myristoyltransferase inhibition (NMTi), today announces the appointment of Dr Chris Martin as independent Chairman to its Board of Directors. Dr Martin is a renowned biotech company founder, director and entrepreneur, and a pioneer and lead |
ADC Therapeutics SA (NYSE:ADCT) Q3 2023 Earnings Call TranscriptADC Therapeutics SA (NYSE:ADCT) Q3 2023 Earnings Call Transcript November 7, 2023 ADC Therapeutics SA beats earnings expectations. Reported EPS is $-0.58, expectations were $-0.61. Operator: Welcome to the ADC Therapeutics Third Quarter 2023 Financial Results Conference Call. My name is Cathy and I will be your operator for today’s call. At this time, all […] |
Q3 2023 ADC Therapeutics SA Earnings CallQ3 2023 ADC Therapeutics SA Earnings Call |
ADC Therapeutics SA (ADCT) Reports Q3 Loss, Lags Revenue EstimatesADC Therapeutics SA (ADCT) delivered earnings and revenue surprises of 4.92% and 0.53%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock? |
ADC Therapeutics Receives NYSE Notice of Non-Compliance With Continued Listing StandardsLAUSANNE, Switzerland, Nov. 07, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that on October 10, 2023, it received a notice from the New York Stock Exchange (NYSE) that the Company is not in compliance with the continued listing minimum price criteria set forth in Section 802.01C of the NYSE Listed Company Manual, which requires listed companies to maintain an average closing share price of at least $1.00 over a consecutive 30 trading-day period. In accordance with S |
ADC Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates3Q 2023 ZYNLONTA®1 net sales of $14.3 million reflect disruption following restructuring of commercial organization, increased competition and higher gross-to-net deductions Operating expenses decreased 23%2 year-over-year due to portfolio prioritization and operational efficiencies; Expected cash runway into mid-2025 Prioritized pipeline progressing with initial data readouts from LOTIS-7 and studies of ADCT-601 targeting AXL and ADCT-901 targeting KAAG1 expected in 1H 2024 Company to host conf |
ADC Therapeutics to Participate in the Jefferies London Healthcare ConferenceLAUSANNE, Switzerland, Nov. 06, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 14th at 10:00 a.m. GMT. A live webcast of the fireside chat will be available via the Events & Presentations page in the Investors section of ADC Therapeutics’ website, ir.adctherapeutics.com. A replay of the webcast will be available for approxim |